; the origin of the third kindred is not known. In the initial report by Staunton and colleagues,5 only four of the eight patients gave a history of affected relatives, and it could not be assumed that all the cases had a genetic basis and if so, whether all the patients had the same disease. If this were the case, it seemed clear that the disorder exhibited reduced penetrance.
Familial amyloid polyneuropathy (FAP) is an autosomal dominant disorder most commonly caused by the deposition of variant transthyretin (TTR) in affected tissues.' It was originally described by Andrade (A Koeppen, personal communication) ; the origin of the third kindred is not known. In the initial report by Staunton and colleagues,5 only four of the eight patients gave a history of affected relatives, and it could not be assumed that all the cases had a genetic basis and if so, whether all the patients had the same disease. If this were the case, it seemed clear that the disorder exhibited reduced penetrance.
We have re-examined all known families with presumed FAP in Donegal and have analysed the TTR gene for the ala 60 mutation in patients and selected relatives. We have also attempted to confirm the suspicion that all these patients, and those reported in the United States, are descended from a common founder by extended pedigree and haplotype analysis. Finally, we carried out a population based study in the particular area of Donegal involved to assess the prevalence of gene carriers among persons not known to be at risk of FAP.
Patients and methods

PATIENTS
The details of the index cases of six of the original families (one index case was illegitimate and no further information was available) and the more recently described family were available to us from earlier studies.56 By contacting and later visiting these families and their relatives, and also the only remaining living patient from earlier studies, we were able to extend the pedigrees originally presented.5 6 We also obtained information from the official local marriage register, which extends back to 1860. All earlier public records relating to pedigrees in Ireland were destroyed in a fire in 1916. Useful information on the origin of surnames came from a special report on the sur- G  T  I  2  A  G  T  I  3  A  G  T  I  4  A  G  T  I  5  A  G  T  I  6  A  G  T  I  7  A  G  T  I  8  AJG  G  T  I/II  9 A/G G/C T/G I/III From this study we can estimate that about 1 % of the population over 45 in a small area of Donegal (fig 1) carry the TTR ala 60 mutation. The sample size was small and therefore the confidence intervals of this estimate were wide. If 1% of the population over the age of 45 have the mutation it is likely that this proportion also applies to the total population in this area, because the population is relatively fixed with some emigration from, but very little immigration into, the area. The total population of the area is 16 414. The predicted number of subjects with the TTR ala 60 mutation in this area is 181 (95% CI 49-378). Even assuming penetrance substantially less than 100%, this suggests that there will be a substantial number of patients with FAP ala 60 presenting in this area over the coming years. It is notable that, over the two years since starting this study, we identified four more cases of FAP ala 60, one of whom was originally detected as an asymptomatic carrier in one of the families, another from the area we studied, and two cases from surrounding areas.
The number of future patients with FAP ala 60 and the ease with which they can now be diagnosed genetically is even more important with the emergence of a potential treatment. Because 90% of TTR is produced in the liver, liver transplantation has been used as a treatment for FAP met 30. Initial studies showed that after liver transplantation only normal TTR could be detected in plasma. '8 Two year follow up of the first four patients transplanted showed that general well being and autonomic function improved and the peripheral neuropathy seemed to arrest with no further deterioration.'9 Further studies are needed to confirm this, and to determine long term outcome and the optimum time for transplantation. It is suggested that patients should be transplanted early as many of the complications are related to the severity of autonomic neuropathy. We are aware of one patient with ITR met 30 who died in the postoperative period because of advanced autonomic failure (unpublished data). It might be difficult to justify liver transplantation in FAP ala 60 given that onset is consistently late. The associated cardiomyopathy might require combined cardiac and liver transplantation, which has been performed in a patient with the tyr 77 mutation.'9 The available evidence suggests that FAP TTR ala 60 will become a medical problem of substantial socioeconomic importance in forthcoming years in this area of Donegal.
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